French Startup Solence Secures Funding to Revolutionize PCOS Treatment with AI
Paris, Thursday, 10 July 2025.
Solence raises €1.6M to innovate AI-driven therapies for PCOS, affecting 20% of women globally. This effort aims to revolutionize care and tackle diagnostic gaps unaddressed by current healthcare.
Introduction to Solence’s AI-Driven Approach
The French startup Solence has secured a seed funding of €1.6 million to foster the development of AI-driven digital therapeutics tailored for Polycystic Ovary Syndrome (PCOS). PCOS, a complex hormonal disorder, impacts approximately 20% of women worldwide, presenting significant challenges in healthcare due to its associated symptoms like infertility and metabolic disorders [1]. The latest investment, spearheaded by Impact Shakers Ventures, underscores a burgeoning interest in digital health solutions that offer a non-traditional approach to managing chronic conditions such as PCOS [1].
Bridging Diagnostic Gaps with AI
Founded by Clara Stephenson, who herself endured a lengthy and challenging diagnostic journey with PCOS, Solence’s mission is to use AI to fill existing gaps in the diagnosis and management of this condition. Research indicates that nearly 85% of women with PCOS remain undiagnosed or inadequately treated, mainly due to the subtlety of its symptoms and variability in presentation [1]. By leveraging AI, Solence aims to personalize treatment plans and predict symptom trends among patients, potentially transforming standard care practices [1].
Innovative Programs and Future Prospects
Solence’s digital platform offers a twelve-week program comprising interactive lessons and personalized advice based on a patient’s unique health profile. This approach is inspired by peer-reviewed research that highlights the effectiveness of lifestyle interventions in managing PCOS symptoms, boosting fertility, and enhancing overall quality of life [1]. As part of its growth strategy, Solence intends to expand its team and forge clinical partnerships, aiming for product development milestones leading toward widespread clinical trials by the end of 2025 [1][2].
Anticipated Impact on Women’s Health
The development of AI therapeutics for PCOS represents a pivotal shift in women’s healthcare, promising more nuanced and effective interventions compared to traditional pharmacotherapy which often comes with significant side effects. With AI promising to cut treatment costs by 20–30%, there is optimism about broadening access to care [2][4]. By addressing the critical needs of women with PCOS, Solence strives not just to treat but to foresee the health trajectories of those affected, underpinning what could be a significant leap forward in tailored medical solutions [4].